person · Reporting owner
ROSA-BJORKESON DAGMAR
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keenova Therapeutics plcMNK · Entity 28960 | Chief Strat & Corp Dev Officer | June 01, 2019 | June 04, 2019 |
| Xencor IncXNCR · Entity 4487 | Director | September 27, 2024 | October 01, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keenova Therapeutics plc
Report date June 01, 2019 · Filed June 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 23,431 |
Reported balance
After 2019-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-06-01 · Tax withholding · Disposed 246 · Balance 23,431 F1: Includes 1,249 shares acquired under the Mallinckrodt employee stock purchase plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,249 shares acquired under the Mallinckrodt employee stock purchase plan.
Xencor Inc
Report date September 27, 2024 · Filed October 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,490 |
Reported balance
After 2024-09-27 transaction · row 1
1 source rowRow 1 · 2024-09-27 · Sale · Disposed 2,503 · Balance 8,490 F1: Sale was pursuant to a 10b5-1 plan arranged to cover withholding taxes upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was pursuant to a 10b5-1 plan arranged to cover withholding taxes upon vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 14,766 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 11,625 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 17,719 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 27, 2024 Filed Oct 1, 2024 20:13 UTC | Xencor Inc XNCR · Entity 4487 | SaleCommon Stock | 2,503 | $20.68 | $51,762.04 |
DisclosureSEC source: 0001127602-24-024682 · form4.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,490 F1 · shares: Sale was pursuant to a 10b5-1 plan arranged to cover withholding taxes upon vesting of restricted stock units. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:24 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 11,971 | $0.00 Strike: $21.31 | $0.00 |
DisclosureSEC source: 0001127602-24-018836 · form4.xml · derivative · entry 2 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,971 Underlying: Common Stock · 11,971 shares Expires 2034-06-12 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 13, 2024, such that the total number of shares will be fully vested on June 13, 2025. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:24 UTC | Xencor Inc XNCR · Entity 4487 | GrantCommon Stock | 5,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018836 · form4.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,993 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,547 | Not disclosed Strike: $9.17 | Not disclosed |
DisclosureSEC source: 0001104659-23-117104 · tm2330435-4_4seq1.xml · derivative · entry 5 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,547 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,790 | Not disclosed Strike: $16.82 | Not disclosed |
DisclosureSEC source: 0001104659-23-117104 · tm2330435-4_4seq1.xml · derivative · entry 4 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,790 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 17,719 | Not disclosed Strike: $17.08 | Not disclosed |
DisclosureSEC source: 0001104659-23-117104 · tm2330435-4_4seq1.xml · derivative · entry 3 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,719 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerCommon Stock | 11,625 | $19.00 | $220,875.00 |
DisclosureSEC source: 0001104659-23-117104 · tm2330435-4_4seq1.xml · nonDerivative · entry 2 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | OtherCommon Stock | 14,766 | $19.00 | $280,554.00 |
DisclosureSEC source: 0001104659-23-117104 · tm2330435-4_4seq1.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:52 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 10,013 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001127602-23-019285 · form4.xml · derivative · entry 2 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,013 Underlying: Common Stock · 10,013 shares Expires 2033-06-20 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 20, 2023, such that the total number of shares will be fully vested on June 20, 2024. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 21:52 UTC | Xencor Inc XNCR · Entity 4487 | GrantCommon Stock | 5,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019285 · form4.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,007 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:39 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,547 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001104659-23-064841 · tm2317083-4_4seq1.xml · derivative · entry 2 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,547 Underlying: Common Stock · 12,547 shares Expires 2033-05-24 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:39 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 8,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064841 · tm2317083-4_4seq1.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,391 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:49 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 21,412 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001127602-22-018169 · form4.xml · derivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,412 Underlying: Common Stock · 21,412 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:16 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,790 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001104659-22-065901 · tm2217184-1_4seq1.xml · derivative · entry 2 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,790 Underlying: Common Stock · 12,790 shares Expires 2032-05-25 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:16 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-065901 · tm2217184-1_4seq1.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,280 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| June 24, 2021 Filed Jun 26, 2021 00:00 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 9,728 | $0.00 Strike: $36.01 | $0.00 |
DisclosureSEC source: 0001415889-21-003229 · form4-06252021_080601.xml · derivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,728 Underlying: Common Stock · 9,728 shares Expires 2031-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 24, 2021, such that the total number of shares will be fully vested on June 24, 2022. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 17,719 | $0.00 Strike: $17.08 | $0.00 |
DisclosureSEC source: 0001104659-21-075217 · tm2118118-4_4seq1.xml · derivative · entry 2 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,719 Underlying: Common Stock · 17,719 shares Expires 2031-05-27 F2 · derivative.exercise_date: 1/3rd of the options subject to the award shall vest and become exercisable on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year). The Vesting Commencement Date is April 1, 2021. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 10,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-075217 · tm2118118-4_4seq1.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,543 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 1/3rd of the shares subject to the award shall vest on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year). The Vesting Commencement Date is April 1, 2021. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 00:49 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 13,953 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001209191-20-039323 · doc4.xml · derivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,953 Underlying: Common Stock · 13,953 shares Expires 2030-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 25, 2020, such that the total number of shares will be fully vested on June 25, 2021. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 22:16 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 15,528 | $0.00 Strike: $38.33 | $0.00 |
DisclosureSEC source: 0001209191-19-061608 · doc4.xml · derivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,528 Underlying: Common Stock · 15,528 shares Expires 2029-12-17 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on December 18, 2020, and the remaining shares vest in equal monthly installments over the subsequent 24 months. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:08 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 246 | $9.06 | $2,228.76 |
DisclosureSEC source: 0000950138-19-000333 · edgar.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Chief Strat & Corp Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,431 F1 · balance_after: Includes 1,249 shares acquired under the Mallinckrodt employee stock purchase plan. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 22:13 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,063 | $22.80 | $24,236.40 |
DisclosureSEC source: 0000950138-19-000231 · edgar.xml · nonDerivative · entry 2 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Chief Strat & Corp Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,428 Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:13 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 34,953 | $0.00 Strike: $22.62 | $0.00 |
DisclosureSEC source: 0000950138-19-000231 · edgar.xml · derivative · entry 3 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Chief Strat & Corp Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,953 Underlying: Ordinary Shares · 34,953 shares Expires 2029-04-01 F2 · derivative.exercise_date: The options vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:13 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 7,638 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000231 · edgar.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Chief Strat & Corp Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,491 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| April 01, 2019 Filed Apr 5, 2019 20:09 UTC Amendment | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 34,953 | $0.00 Strike: $22.26 | $0.00 |
DisclosureSEC source: 0000950138-19-000235 · edgar.xml · derivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Chief Strat & Corp Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,953 Underlying: Ordinary Shares · 34,953 shares Expires 2029-04-01 F1 · derivative.exercise_price: This amended Form 4 is being filed to correct a typographical error in the exercise price of the options which was previously reported as $22.62. F2 · derivative.exercise_date: The options vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:14 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 247 | $17.05 | $4,211.35 |
DisclosureSEC source: 0000950138-18-000446 · edgar.xml · nonDerivative · entry 1 ROSA-BJORKESON DAGMAR · CIK 0001643934 · Chief Strat & Corp Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,853 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.